IBRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ImmunityBio Inc (IBRX) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock is experiencing significant negative price momentum, legal challenges, and lacks clear positive trading signals. While the company has shown impressive revenue growth and has strong analyst support, the ongoing lawsuits and recent price drops introduce uncertainty. It is advisable to hold off on investing until the legal issues are resolved and the stock demonstrates more stability.
The MACD is negatively expanding (-0.229), RSI is neutral at 37.78, and moving averages are converging, indicating no clear upward momentum. The stock is trading below its pivot level (8.124) and closer to its first support level (6.978), suggesting bearish sentiment.
Significant revenue growth of 406.95% YoY in Q4
Strong analyst support with multiple Buy ratings and price target increases, citing ANKTIVA's growth and regulatory approvals.
Positive interim analysis for QUILT-2.005 clinical trial, with potential for supplemental BLA submission in 2026.
Class action lawsuits alleging misleading statements by the company, which could lead to financial penalties and reputational damage.
Recent price drop of -8.55% in regular trading and -2.60% in pre-market.
No significant hedge fund or insider trading activity, indicating a lack of strong institutional confidence.
In Q4 2025, revenue increased to $38.29M (+406.95% YoY), but net income remains negative at -$61.94M (+4.70% YoY). EPS dropped to -0.06 (-25% YoY), and gross margin slightly declined to 99 (-1% YoY). While revenue growth is impressive, profitability remains a concern.
Analysts are bullish on the stock, with BTIG assigning a Buy rating and a $13 price target, Piper Sandler raising its target to $12, and H.C. Wainwright increasing its target to $15. Analysts cite strong ANKTIVA growth, regulatory approvals, and commercial execution as key drivers for future appreciation.
